pul-042
Small moleculeexperimental
Clinical trial activity
7 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02124278)
Timeline
Indications
Mechanism of action
- Toll-like receptor 9AGONIST
TLR9 agonist
- Toll-like receptor 6AGONIST
TLR6 agonist
- Toll-like receptor 2AGONIST
TLR2 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pul-042
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06665100 | Phase 2 | Oct 31, 2025 | Pulmotect, Inc., State of Texas |
| NCT04312997 | Phase 2 | Apr 30, 2020 | Pulmotect, Inc. |
| NCT04313023 | Phase 2 | Apr 30, 2020 | Pulmotect, Inc. |
| NCT03794557 | Phase 2 | Jan 21, 2019 | Data Magik Ltd, MWB Consulting Ltd, Pulmotect, Inc., University of London, Virtus Pharms |
| NCT03097796 | Phase 1 | Apr 1, 2017 | National Heart, Lung, and Blood Institute (NHLBI), Pulmotect, Inc., State of Texas, University of Texas at Houston |
| NCT02566252 | Phase 1 | Jul 1, 2015 | Pulmotect, Inc., WCCT Global |
| NCT02124278 | Phase 1 | Feb 1, 2014 | Pulmotect, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pulmotect, Inc. | For profit | 7 | 7 | 2 | 2014 |
| State of Texas | Government | 2 | 0 | 2 | 2017 |
| Data Magik Ltd | For profit | 1 | 0 | 1 | 2019 |
| MWB Consulting Ltd | For profit | 1 | 0 | 1 | 2019 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2017 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Virtus Pharms | For profit | 1 | 0 | 1 | 2019 |
| WCCT Global | For profit | 1 | 0 | 1 | 2015 |
9 organizations
Page 1 / 1